MACK

Stats

Summary

merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. through systems biology, which brings together the fields of biology, computing and engineering, merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. such an approach has the potential to make individualized treatment of patients a reality. merrimack's first commercial product, onivydetm (irinotecan liposome injection), was approved by the u.s. fda on october 22, 2015. with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, merrimack is building one of the most robust oncology pipelines in the industry. for more information, please visit merrimack's website at www.merrimack.com or connect on twitter at @merrimackpharma.

Market Cap: 211 Million

Primary Exchange: NASDAQ

Website: merrimack.com

Shares Outstanding: 14.3 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.22053312413951942

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 2468 trading days

From: 2015-04-23 To: 2024-03-07

Lowest Point:

Ex-Date	Payment Date	Record Date	Declared Date	Amount	Flag	Dividend Type	Qualified	Indicated
2019-08-27	2019-09-05	2019-08-28	2019-07-25	1.5	Special
2019-12-13	2019-12-23	2019-12-16		0.5	Cash
2019-09-06	2019-09-05	2019-08-28	2019-07-24	1.4966750144958496	Cash

Ex-Date	Declared Date	Record Date	Payment Date	Ratio	To Factor	For Factor
2017-09-06				10.0	1.0	10.0